Introduction
============

A prospective observational study on molecular adsorbent recirculating system (MARS) therapy in a liver-disease-dedicated ICU.

Methods
=======

From January 2004 to November 2009, all patients with an acute liver failure fulfilling MARS therapy criteria, in relation to two main indications: primary and secondary to chronic liver failure (ALF/ACLF = group 1) or intractable pruritus (IP = group 2), were included: Data were collected before and after each MARS procedure. APACHE and MELD scores \[[@B1]\] were used to predict the ICU mortality and the 90-day mortality, respectively.

Results
=======

Thirty-nine patients, APACHE II = 41 (21 to 86); MELD = 29 (14 to 47), having received 98 treatments (one to five treatments), were included. The overall mortality was n = 22 (56%). Since 35 patients have been treated for ALF/ACLF, 15 underwent a liver transplantation (OLT) (see Figure [1](#F1){ref-type="fig"}). The 90-day mortality of the 20 patients from group 1 without OLT was 44%, compared with 76% predicted by the MELD score. MARS was effective to decrease the bilirubin levels -35% (of the pretreatment rate which was 30 times the baseline), *P*\< 0.01, the ammoniemia levels -50% (of the pretreatment rate which was four times the baseline), *P*\< 0.01, and serum creatinine levels -40% (of the pretreatment rate which was two times the baseline). The MARS therapy was also effective to improve the pruritus after two treatments in the group 2 patients. A single severe complication was noticed as hemorrhagic shock quickly resolved in one patient (group 1).
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Conclusions
===========

MARS therapy improves liver function in patients with both acute and chronic liver failure, and allows those patients to wait until OLT, if necessary. Furthermore it also improves the 90-day survival of patients with ACLF having no OLT indication.
